Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Molecular design and delivery of extracellular and membrane protein degradation chimeras.

Created on 07 Sep 2026

Authors

Shutong Lin, Huiling Zhou, Jiayan Qiu, Yijing Dang, Longfa Kou, Zheying Zhu, Zhiai Xu, Yi Lai, Haijun Yu

Published in

Advanced drug delivery reviews. Pages 115959. Sep 06, 2026. Epub Sep 06, 2026.

Abstract

Extracellular and membrane-associated proteins constitute a substantial therapeutic target space that remains largely inaccessible to intracellular degradation strategies based on the ubiquitin-proteasome system. Membrane and extracellular targeted protein degradation (meTPD) addresses this limitation by coupling target recognition to degradation-competent uptake and intracellular sorting rather than relying on a single receptor or platform. In this Review, we organize meTPD strategies according to their trafficking and degradation routes, including lysosome-targeting receptor-dependent systems, transmembrane E3 ligase recruitment, receptor-independent internalization, lysosomal-sorting sequences and autophagy-mediated clearance. We then examine how ligand affinity and epitope accessibility, ternary-complex geometry, linker architecture, covalency, valency, receptor recycling and degrader reuse collectively determine productive degradation. Particular attention is given to spatial selectivity across tissues, cell populations and subcellular organelles, as well as to artificial intelligence-assisted design, stimuli-responsive activation and delivery systems that regulate the exposure and trafficking of meTPDs. Finally, we discuss emerging clinical evidence, convergence with antibody-drug conjugate-derived modalities, the hook effect and plausible resistance mechanisms. By integrating molecular design, receptor biology, intracellular trafficking, delivery and pharmacodynamic considerations, this Review provides a framework for selecting disease-matched degradation routes and advancing meTPDs from platform-specific demonstrations towards predictable therapeutic modalities.

PMID:
42702251
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement